



ASSESSMENT OF THE RISK OF TOXICITY OF FLUOROPYRIMIDES AND IRINOTECAN

Complete, date and sign the consultation certificate and consent for all genotyping requests

For phenotyping: 1 tube of 5-7 ml of whole blood in an EDTA or heparin tube **WITHOUT GEL**, decanted and frozen. The maximum time between collection and centrifugation is 1 hour if the sample is stored at room temperature, and 4 hours if stored between +2°C and +8°C, with centrifugation preferably at +4°C. The centrifugation speed is > 15 minutes at 1500 to 2000 g or > 10 minutes at 2000 to 2500 g. Standard **double** centrifugation, with plasma decanting between the two steps (achieving a residual platelet count of < 10 x 10⁹/l). Immediate freezing of the obtained plasma, transport must respect the cold chain (strictly frozen). **Mark "URGENT"** on the plastic bag.

Pour un Génotypage : 1 5-7mL EDTA whole blood tube Shipment at room temperature and made within 7 days maximum.

TESTING LABORATORY	SAMPLING
N° Client: <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> C / <input type="text"/>	Sampling date: <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/>
Mandatory Stamp	For phenotyping, the following must be specified:
	Sampling time <input type="text"/> <input type="text"/> h <input type="text"/> <input type="text"/>
	Centrifugation time <input type="text"/> <input type="text"/> h <input type="text"/> <input type="text"/>
	Freezing time <input type="text"/> <input type="text"/> h <input type="text"/> <input type="text"/>

PATIENT	PRESCRIBER
Surname	Surname
First name.....	First name.....
Maiden name.....	Address
Address	City
City	Country
Date of birth: <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/>	Tél. Fax
	E-mail address:
	Signature :

REQUESTED TEST	
<input type="checkbox"/> DPD PHENOTYPING (plasma uracil) Indication : <input type="checkbox"/> Before Treatment (OPL code: DPDFP) Screening before initiating fluoropyrimidine therapy <input type="checkbox"/> Toxicity – Reintroduction (OPL code: DPDTX) <input type="checkbox"/> Treatment already initiated (OPL code: DPDAU)	<input type="checkbox"/> DPYD GENOTYPING (OPL code: DPDGE) Analysis of the DPYD*2A, D949V and DPYD*13 variants according to recommendations <input type="checkbox"/> UGT1A1 GENOTYPING (OPL code: UG1A1) Promoter analysis <input type="checkbox"/> DPYD AND DPYS GENOTYPING Full analysis (coding regions and intron/exon junctions +/-50bp) of the genes

DECLARATION OF CONSULTATION BY THE PRESCRIBING PHYSICIAN OR GENETIC COUNSELLOR ACKNOWLEDGEMENT OF RECEIPT OF INFORMATION AND CONSENT FOR GENETIC TESTING *to be completed, dated and signed mandatory for Genotyping requests*

I, the undersigned, Dr/Pr..... or Mr/Mrs genetic counselor under the supervision of Dr/Pr..... certify that I have informed the undersigned patient and his/her parents (legal representatives) about the characteristics of the investigated disease or genetic susceptibility to drug treatment, how to diagnose it, how to prevent and treat it, how the disease is transmitted and the possible consequences in other members of the family, the storage of the sample, and that I have obtained the consent of the patient AND his/her guardianship under the conditions provided for by the French public health code (articles R1131-4 and 5).

I, the undersigned, Mr, Mrs..... born on

Living in:
Acknowledge that I have received information on the genetic testing that will be performed to assess my genetic susceptibility to drug treatment from Dr/Pr....., I have been informed of my right to request (at any time) that this study be interrupted; that the results be withheld from me; and/or that my stored samples be destroyed.

I will receive the results of these tests, and the prescribing physician (or genetic counsellor) will explain them to me, based on the current state of knowledge

To this end, I consent: ☐ to the collection of my sample ☐ to the collection of my minor child's sample or an adult under guardianship's sample

☐ I consent to its use, where appropriate, for scientific research purposes. In this case, all my medical data will be protected through total anonymization. Therefore, I am aware that I will not receive any benefit or have any prejudice from these scientific studies.

PATIENT ID (Signature)	LEGAL GUARDIAN (Signature)	PRESCRIBER (Signature)
Surname, First name, Date of birth	Surname, First name, Date of birth,	Surname, First name,
Signature	Signature	Signature
	If the patient is minor or an adult under guardianship, relationship to the patient:	

Done in, On